"Method Of Producing Regulatory T Cells By Culturing Regulatory T Cells Obtained From Umbilical Cord Blood" in Patent Application Approval Process (USPTO 20240182855).

A patent application has been filed for a method of producing regulatory T cells (Tregs) by culturing Tregs obtained from umbilical cord blood. Tregs are important for deactivating excessive immune responses and maintaining immune balance. Patients with autoimmune diseases or graft-versus-host disease have fewer Tregs or abnormal Treg function. The method described in the patent application aims to overcome the challenges of obtaining a large number of highly purified expanded Tregs and maintaining the stability of the Tregs during expansion. The method involves culturing the initial population of Tregs in a specific media containing an oligonucleotide sequence, and optionally TGFb1 and rapamycin. The patent application also discusses the potential use of these expanded Tregs in treating autoimmune diseases. [Extracted from the article]